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Fibulin-1 is an extracellularmatrix (ECM) protein, levels of which are elevated in serumand lung tissue from
patients with idiopathic pulmonary fibrosis compared to healthy volunteers. Inhibition of fibulin-1C, one of
four fibulin-1 isoforms, reduced proliferation and wound healing in human airway smooth muscle (ASM)
cells. This study identified the bioactive region/s of fibulin-1C which promotes fibrosis. Seven fibulin-1C
peptides were synthesized and used to pre-coat tissue culture plates before lung derived ASM cells and
fibroblasts from patients with pulmonary fibrosis (PF), chronic obstructive pulmonary disease (COPD) or
neither disease (Control) were plated. Peptide effects on in vitro measures of fibrosis: cell attachment,
proliferation and viability, and ECM deposition, were examined. Among these peptides, peptide 1C1
(FBLN1C1) enhanced ASM cell and fibroblast attachment. FBLN1C1 increased mitochondrial activity and
proliferation in fibroblasts. In addition, FBLN1C1 stimulated fibulin1 deposition in PF and COPD
fibroblasts, and augmented fibronectin and perlecan deposition in all three groups. Peptides FBLN1C2 to
FBLN1C7 had no activity. The active fibulin-1C peptide identified in this study describes a useful tool for
future studies. Ongoing investigation of the role of fibulin-1 may reveal the mechanisms underlying the
pathphysiology of chronic lung diseases.
P ulmonary structural remodelling is a feature of the lungs in both pulmonary fibrosis (PF) and chronicobstructive pulmonary disease (COPD)1–4. The remodelling includes alterations in the interstitial tissue,such as accumulation or destruction of extracellular matrix (ECM), and changes in the number and
functions of parenchymal cells. In PF, there is an increased lungmatrix deposition and proliferative and activated
fibroblasts in the parenchyma3,5. In COPD, there is a destruction of the alveolar walls and interstitial tissue,
termed emphysema, in the lung parenchyma2. However, some specific ECM proteins per weight unit are
increased in the lungs of patients with emphysema compared to patients without emphysema6–8. Furthermore,
peripheral airways in COPD, especially those close to emphysematous destruction, have thickened airway walls
and augmented deposition of ECM9,10. The mechanisms of the development of these pathologies present in the
lungs with COPD or PF are complicated. One of the remaining unanswered questions is how altered ECM
proteins influence the persistence of lung remodelling in COPD and PF.
The ECM is a complex structured network of macromolecules which form the scaffold of the human lung.
ECM proteins can be produced by immune and lung structural cells including epithelium, airway smoothmuscle
(ASM) cells and fibroblasts. However, fibroblasts are one of the major producers of ECM proteins11. The
interaction between the ECM and the cells is dynamic, and ECM proteins can influence cellular phenotype
and function12. Among these ECM proteins, fibulin-1 is a member of the fibulin protein family which consists of
seven members (fibulin-1 to -7) in humans. Fibulin-1 is localized in the basement membrane and connective
tissue in human lung and is associated withmany ECMproteins to facilitate ECM functions13,14. Altered fibulin-1
levels are associated with tumour cells, chronic liver and kidney disease, diabetes and asthma15–19.
Fibulin-1(FBLN1) has four isoforms, named as FBLN1A, B, C, and D, which are splice variants possessing
different C-terminal sequences. The different isoforms of fibulin-1 have variable functions. ECM FBLN1D
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decreases the invasive phenotype and tumour formation in human
fibrosarcoma-derived cell lines and regulates the expression ofmetal-
loproteinases in breast cancer cells19,21. In contrast, an increased
FBLN1C:FBLN1D ratio has been found in ovarian cancer cells and
this increase is associated with the oestrogen receptor-a, which med-
iates the growth of epithelial ovarian carcinomas22,23.
Little is known about the function of FBLN1C, nor the regions
which mediate its biological activity. In our previous research we
have found that the level of fibulin-1 is elevated in the serum and
bronchoalveolar lavage fluid of patients with asthma compared to
people without asthma, and serum and tissue fibulin-1 levels are
increased in the patients with IPF compared to those without lung
diseases17,24. Furthermore we have found that gene silencing of
FBLN1C reduced cell proliferation and wound healing of ASM cells
and reduced features of lung disease in a murine model17. Given the
important biological role of FBLN1C, the aim of this study was to
identify the active part/s of the molecule and to further characterise
the biological role of FBLN1C. This study was presented at the
Thoracic Society of Australia & New Zealand Annual Scientific
Meeting 201425 and the American Thoracic Society International
Conference 201426.
Results
FBLN1C1 peptide increased the attachment of ASM cells and lung
fibroblasts. To identify which regions of FBLN1C had biological
activity, we seeded primary human lung fibroblasts and ASM cells
in wells coated with seven peptides generated from FBLN1C,
FBLN1C1, 2, 3, 4, 5, 6 and 7 (Fig. 1 and supplementary information
Table 4), and assessed the effects on cellular attachment and viability/
proliferation as measured via MTT assay. FBLN1C1 (3 and 10 mg/ml)
enhanced cell attachment of both fibroblasts and ASM cells, while
FBLN1C2 (3 and 10 mg/ml) increased attachment only in
fibroblasts. FBLN1C3, 4, 5, 6 and 7 (3 and 10 mg/ml) did not have
any effect on cell attachment either in fibroblasts or in ASM cells
(Table 1 and supplementary information Table 1).
FBLN1C1 peptide increased cell viability/proliferation of lung
fibroblasts. FBLN1C1 (3 and 10 mg/ml) increased cell viability/
proliferation fibroblasts (Table 2 and supplementary information
Table 2). In contrast, FBLN1C2, 3, 4, 5, 6 and 7 (3 and 10 mg/ml)
did not modulate viability/proliferation in lung fibroblasts. None of
the FBLN1C peptides changed ASM cell viability/proliferation
(Table 2 and supplementary information Table 2). Human plasma
FN (hFN, 3 and 10 mg/ml) was used as a positive control in these
experiments and it stimulated cell attachment and viability/
proliferation of both lung fibroblasts and ASM cells (Table 1 and
2, supplementary information Table 1 and 2).
In light of the lack of activity observed with FBLIN1C2, 3, 4, 5 & 7
these peptides were not further interrogated in this study, however
FBLN1C6 was maintained in the experimental setup as a negative
control peptide. In all subsequent experiments we used only fibro-
blasts as ASM viability/proliferation was not modulated by
FBLN1C1.
Since FBLN1C1 increased fibroblast viability/proliferation, we
tested the effect of FBLN1C1 on fibroblast proliferation using man-
ual cell counting. FBLN1C1 stimulated fibroblast proliferation, at a
concentration of 10 mg/ml (Fig. 2) (fold increase compared to
uncoated wells were 1.16 6 0.14 and 1.32 6 0.07, P , 0.05 for
3 mg/ml and 10 mg/ml of FBLN1C1, respectively, n 5 4). The cell
number was also augmented by hFN (3 mg/ml) but not FBLN1C6
(10 mg/ml, Fig. 2) (fold increase compared to uncoated wells were
1.73 6 0.21, P , 0.05 and 1.12 6 0.071 for hFN and FBLN1C6,
respectively, n 5 4). The data from these studies showed that
FBLN1C1 at a concentration of 10 mg/ml was effective in promoting
fibroblast attachment, viability and proliferation.
To compare that the biological properties of FBLN1C1 with the
full length human FBLN1C, we purified FBLN1C fromHT1080 cells
that were stably transfected with full length hFBLN1C plasmid to use
in cell attachment assays. We found that FBLN1C protein (3 mg/ml)
had similar effects as FBLN1C1 (10 mg/ml) on fibroblast attachment
(Fig. 3a).
FBLN1C1 differentially regulated cell attachment, viability and
proliferation in lung fibroblasts. To further understand the
biological activity of FBLN1C we investigated if it had differential
effects in fibroblasts isolated from patients with lung diseases with
varying amounts of fibrosis. COPD is characterised by relatively
minor lung fibrosis in comparison to PF. In addition we used cells
from patients that were not diagnosed with either disease (control).
Comparing the three groups of lung fibroblasts, the basal levels of
cell attachment were highest in PF cells when compared to COPD
and control cells (Fig. 3b, 0.0336 0.009, n5 5, 0.0676 0.015, n5 7
and 0.074 6 0.009#, n 5 8 for control, COPD and PF, respectively.
Data are expressed as Mean 6 SE of absorbance at 595 nm. #, P ,
0.05, one-way ANOVA, compared to control). FBLN1C1 increased
fibroblast attachment in the Control andCOPDgroups but not in the
PF group (Fig. 3b). Fibroblast attachment was enhanced by the pos-
itive control (FN, 3 mg/ml) in all three groups (Control, 508.5 6
89.15, n 5 5, P , 0.001; COPD, 323.5 6 45.82, n 5 7, P , 0.01;
Figure 1 | The schematic diagram of Fibulin-1C peptides. FBLN1C1-7,
fibulin1C peptide 1–7.
Table 1 | The effect of FBLN1C peptides on cell attachment in fibroblasts and ASM cells
Cell type
Peptides FBLN1C hFN
1 2 3 4 5 6 7
Fibroblast N 5 5 " " ---- ---- ---- ---- ---- "
ASM cell N 5 6 " ---- ---- ---- ---- ---- ---- "
Lung fibroblasts and airway smooth muscle (ASM) cells were seeded on procoated wells for 2 hrs. The wells were washed and stained with toluidine blue. Results are detected at 595 nm subtracted with
background. N 5 5 for fibroblast, 3/5 control, 2/5 chronic obstructive pulmonary disease (COPD). N 5 6 for ASM cell, 4/6 control, 2/6 COPD. FBLN1C1-7, fibulin1C peptide 1-7. hFN, human
fibronectin. The concentrations of FBLN1C1-7 and hFN, used for experiments, were 3 and 10 mg/ml. ", P, 0.05 significantly increased compared to PBS; - - - - no change compared to PBS; repeatedOne-
way ANOVA with Dunnett’s multiple comparison test was performed.
www.nature.com/scientificreports
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PF, 319.06 56.54, n5 8, P , 0.001; data expressed as Mean6 SE,
percentage change compared to unstimulated; supplementary
information Fig. 1).
Cell viability/proliferation under unstimulated conditions (no
protein coating or proproliferative stimulus) was similar between
control, COPD and PF fibroblasts. FBLN1C1 (10 mg/ml) increased
viability/proliferation in all three groups (Fig. 4a), as did hFN (3 mg/
ml, supplementary information Fig. 2a). However, FBLN1C1 (10 mg/
ml) enhanced proliferation of the control group (Fig. 4b). Similar
growth patterns were observed in fibroblasts treated with hFN (3 mg/
ml) in all three groups of cells (supplementary information Fig. 2b).
FBLN1C1 increased ECMFBLN1, EDA-FN and perlecan deposition.
To investigate if FBLN1C1 could promote the production of ECM
proteins, the deposition of FBLN1, cellular-FN and perlecan by
fibroblasts was investigated. To avoid cross detection, antibodies
specific for fibulin-1 N-terminal domain and EDA-FN were used in
the ELISA which ensured that peptide FBLN1C1 and hFN were not
detected. FBLN1C1 (10 mg/ml) stimulated FBLN1 deposition in
fibroblasts from COPD and PF groups while hFN (3 mg/ml) had no
effect on FBLN1 production in all three groups (Fig. 5a). Both
FBLN1C1 (10 mg/ml) and hFN (3 mg/ml) increased EDA-FN and
perlecan deposition in all three groups (Fig. 5b and c).
FBLN1C1 and hFN decreased TGFb1 release in lung fibroblasts.
Since TGF b 1 plays a critical role in ECM regulation, we explored the
possibility that FBLN1C1 induced responses in lung fibroblasts are
mediated through the release of TGFb1, a known potent pro-fibrotic
stimulus for fibroblasts. Both FBLN1C1 (10 mg/ml) and hFN (3 mg/
ml) decreased TGFb1 release in all three groups (Fig. 6).
Discussion
This study is, to our knowledge, the first to characterise the direct
biological function of fibulin1C on mesenchymal cells. The active
region within FBLN1C which stimulated cell attachment, viability,
proliferation, and ECM protein production by lung fibroblasts was
identified. FBLN1C1 differentially regulated cell proliferation and
ECM FBLN1 deposition in fibroblasts from patients with or without
COPD or PF.
Both lung fibroblasts and ASM cells were used in the initial experi-
ments. The increase in cell attachment in both fibroblasts and ASM
cells indicate that FBLN1C1 may have the same binding site in these
two types of mesenchymal cells. The finding that FBLN1C1
enhanced fibroblast viability and proliferation indicated that the
cellular signalling of FBLN1C1 may be different in fibroblasts com-
pared to ASM cells.
The attachment of fibroblasts is a critical step in both proliferation
and migration, and as such for the development of fibroblastic foci.
This study demonstrated that the FBLN1C1 peptide increased cell
attachment in the control and COPD groups. In the PF group,
FBLN1C1 did not further enhance fibroblast attachment. This may
be due to the elevated attachment levels under basal conditions in PF
cells as presented in the current study.
The augmented viability and proliferation induced by FBLN1C1
in fibroblasts from all three groups indicated that FBLN1C1 has a
dynamic role in fibroblast activation. However, the mechanism of
this activation is unknown. hFN, the control protein used in the
study, is the predominant component of FN-based fibrillar matrices,
and has been found to stimulate attachment, proliferation, migration
and differentiation as well as activation of inflammatory response in
fibroblasts27,28. All the cells used in this study responded to hFN in
terms of attachment and viability. However, there is no homology
between the FBLN1C1 amino acid sequence and the hFN sequence of
three amino acids or more. Therefore, it is unlikely that FBLN1C1
and hFN share the same mechanism in regulating fibroblast attach-
ment and mitochondrial activity.
It is interesting that FBLN1C1 increased fibroblast proliferation in
the control group, as did hFN. This result is consistent with the
finding observed by Lau et al. that silencing FBLN1C decreased
ASM cell proliferation17. Data from other studies show that the pro-
liferation rates of fibroblasts from patients with COPD or PF are
different from those from controls. However, the results from those
studies are contradictory, with some reporting increased and some
decreased proliferation. In addition, fibroblasts from COPD or PF
lungs also have differential proliferative responses to various stimuli
compared to control cells5,29,30. In the current study, although we did
not find differences in fibroblast proliferation under basal conditions
in all three groups, the increase in cell number in the presence of
FBLN1C1 in only the control group illustrated that fibroblasts from
the COPD and PF groups had distinct responses to FBLN1C1 with
respect to cell proliferation. It is possible that the fibroblast prolif-
eration patternmay differ when FBLN1C1 is added in the presence of
other stimuli.
Mitochondria play an important role in cell growth and the MTT
assay is often used as a surrogate for cell viability and proliferation
Table 2 | The effect of FBLN1C peptides on cell mitochondrial activity in fibroblasts and ASM cells
Cell type
Peptides FBLN1C hFN
1 2 3 4 5 6 7
Fibroblast N 5 4 " ---- ---- ---- ---- ---- ---- "
ASM cell N 5 5 " ---- ---- ---- ---- ---- ---- "
Lung fibroblasts andairway smoothmuscle (ASM) cellswere seededonprecoatedwells for 3 days and incubatedwithMTT for 4 hrs.MTT formazanwasdissolved in10%SDSand the intensity of blue colour
detected using a SpectraMaxM2 plate reader. Data were collected fromN5 4 for fibroblast, 3/4 control, 1/4 chronic obstructive pulmonary disease (COPD); and N5 5 for ASM cell, 4/5 control, 1/5
COPD. FBLN1C1-7, fibulin1Cpeptide1-7; hFN, human fibronectin. The concentrations of FBLN1C1-7 andhFN, used for experiments,were 3and10 mg/ml. ", P,0.05 significantly different compared to
PBS; - - - - no change compared to PBS; repeated One-way ANOVA with Dunnett’s multiple comparison test was performed.
Figure 2 | Fibulin-1C peptide 1 (FBLN1C1) induces lung fibroblast
proliferation. Fibroblasts were seeded in 12-well plates, coated with
FBLN1C6 (10 mg/ml, shaded bar) or FBLN1C1 (3 mg/ml, grey bar; 10 mg/
ml, black bar) or neither (PBS, open bar) in 0.1% FBS DMEM and were
manually counted 3 days later. N5 4, 2/4 control, 2/4 chronic obstructive
pulmonary disease. * P , 0.05, significantly different from PBS; repeated
One-way ANOVA with Dunnett’s multiple comparison test was
performed.
www.nature.com/scientificreports
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assay inmany cases, including in transformed fibroblast cell lines and
ASM cells31,32. However, the number of mitochondria per cell is not
static and is altered in respiratory diseases33. Thus, the increase in
mitochondrial activity may not reflect cell proliferation, as we
observed in the COPD and PF groups in this study.
One of the important findings in this study is the increased depos-
ition of ECM proteins induced by FBLN1C1. In addition to cellular-
FN, we also measured perlecan. Perlecan is a major heparin sulphate
proteolycan in connective tissue whose function is mainly dependant
on binding and presentation of growth factors to high-affinity tyr-
osine kinases receptors34. In particular, fibroblast growth factor-
binding protein is a key ligand for perlecan35. Through this
interaction, perlecan promotes functions of fibroblast growth factor
and it also increases cell attachment in ASM cells from patients with
COPD36,37. The augmented deposition of cellular-FN and perlecan
modulated by FBLN1C1 may enhance fibroblast activity and extend
fibroblast induced remodelling in the lung.
The most interesting finding of this study is that FBLN1C1
increased fibulin-1 deposition in COPD and FP groups. In contrast
to cellular-FN and perlecan deposition, fibulin-1 production was not
induced by hFN. This specific induction of fibulin-1 in fibroblasts in
COPD and PF group indicated that FBLN1C may play a crucial role
in lung remodelling in COPD and PF. We have shown that TGFb1
was down regulated by FBLN1C1 which indicated that the FBLN1C1
induced cell attachment, proliferation and ECM deposition in lung
fibroblasts is not dependent on the TGFb1 signalling pathway.
Further studies are needed to investigate the mechanisms underlying
these cellular responses which may help understanding the patho-
genesis of COPD and PF.
There is currently very little known information relating to
FBLN1C, such as the receptors to which it binds, and an inadequacy
which is not advanced by the lack of a commercially available source
of FBLN1C protein for research. These limitations restrict research-
ers’ endeavours to further investigate the functional roles of FBLN1C
protein. To our knowledge, this is the first study that has investigated
the activity of the specific regions of FBLN1C using peptides. The
active peptide identified in this study describes a useful tool for future
studies. Ongoing investigation of the role of fibulin-1 may reveal the
mechanisms underlying the pathphysiology of chronic lung diseases.
Methods
Study subjects and primary lung cell culture. All experimental protocols using
human lung tissue and information related to study subjects were approved by the
Ethics Review Committee of the SouthWest Sydney Area Health Service, the Human
Research Ethics Committee of The University of Sydney and St Vincents Hospital.
ASM cells and distal lung fibroblasts (fibroblasts) were obtained and maintained as
previously described38,39. All methods were carried out according to guidelines set by
The University of Sydney. Briefly, ASM cells were isolated from medium to large
airways and fibroblasts were derived from proximal lung tissues which were obtained
frommacroscopically normal surgical tailings following resection for thoracic lesions,
and from lung transplantation for emphysema or pulmonary fibrosis. All study
subjects provided written informed consent. ASM cells and fibroblasts were
Figure 3 | Fibulin-1C peptide 1 (FBLN1C1) and fibulin-1C (FBLN1C) protein increase lung fibroblasts attachment in control and COPD groups.
Fibroblasts were seeded in 96-well plates, coated with FBLN1C protein (shaded bar) or FBLN1C1 (black bars) or neither (PBS, open bars) in 0.1% FBS
DMEM. After 2 hours, cells were fixed and stained with 0.5% toludine blue solution. The dye bound to cells was solubilised using 1% SDS solution and
the intensity of blue colour was detected at a wavelength of 595 nm. The results are absorbance subtracted background and expressed asmean6 SEM. (a)
fibroblast attachment stimulated by fibulin-1C protein 3 mg/ml and FBLN1C1 10 mg/ml; N 5 4, 2/4 are control and 2/4 are chronic obstructive
pulmonary disease (COPD). (b) fibroblast attachment stimulated by FBLN1C1 10 mg/ml; Control N5 5, COPDN5 7, pulmonary fibrosis (PF) N5 8.
*P, 0.05, significantly different fromPBS; two-wayANOVAwith Bonferroni post test was performed. # P, 0.05, significant difference betweenControl
and PF at basal levels; one-way ANOVA with Bonferroni’s multiple comparison test was performed.
Figure 4 | Fibulin-1C peptide 1 (FBLN1C1) increases cell viability and proliferation in lung fibroblast. Fibroblasts were seeded in the plates coated with
(black bars) or without (PBS, open bars) FBLN1C1 10 mg/ml in 0.1% FBS DMEM for 3 days. (a) MTT was added into wells and converted to MTT
formazan, which was dissolved using 10% SDS solution. The intensity of blue colour was detected at a wavelength of 570 nm subtracted with a reference
wavelength 690 nm. The results are absorbance corrected with background and expressed as mean 6 SEM. Control N 5 5, chronic obstructive
pulmonary disease (COPD) N 5 7, pulmonary fibrosis (PF) N 5 9. (b) manual cell counting for fibroblasts. The results are cell number per well and
expressed as mean6 SEM. Control N5 5, COPDN5 4, PF N5 9. * P, 0.05, significantly different from PBS; two-way ANOVA with Bonferroni post
test was performed.
www.nature.com/scientificreports
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maintained in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, Grand Island,
New York, US) with 5% foetal bovine serum (FBS) and 1% Antibiotic-Antimycotic
(Gibco, Grand Island, New York, US). The cells were mycoplasma free and used in
experiments between passage 4 to 7 for ASM cells and passage 2–5 for fibroblasts,
respectively. The disease states of the patients were confirmed by doctor diagnosis. In
this study, the cells were categorized into three groups according to doctors’
diagnosis: (1) control group, cells from macroscopically normal surgical tailings of
patients with lung cancer but no airway obstruction (FEV1: FVC$ 70%); (2) COPD
group, cells from lung resection or transplantation of patients withmoderate to severe
airway obstruction; (3) pulmonary fibrosis (PF) group, cells from explanted lungs of
patients with severe lung fibrosis. The patient demographics and which cells were
used for experiments in the comparisons of the three groups are shown in
supplementary information table 3.
FBLN1C peptide design. The FBLN1C C-terminal specific region starts at amino
acid 567 (NCBI Ref NP-001987.2). Seven sequential fibulin-1C specific peptides
(Auspep, Tullamarine, Vic, Australia) were designed according to the principles
described by Angeletti40. The sequences of peptides FBLN1C-1-7 are listed in
supplementary information table 4. Figure 1 shows the schematic diagram of Fibulin-
1C peptides which illustrates the overlapping peptide design strategy.
Cell experiments.The plastic cell culture plates were coated with or without FBLN1C
peptides at concentrations of 3 and 10 mg/ml for 20 hours (hrs) at room temperature
(RT). The plates were washed three times with phosphate buffered saline (PBS)
following coating and then blocked with 1% bovine serum albumin (BSA, Sigma-
Aldrich, St. Louise, MO) in PBS for 1 hour (hr) at RT. After the plates were washed,
ASM cells and fibroblasts were plated in DMEM containing 0.1% FBS (DMEM/FBS).
96-well plates were used for attachment, mitochondrial activity (MTT) assay and
ECM deposition experiments and cells were seeded in triplicate for each treatment.
12-well plates were used for the proliferation assays. Human plasma fibronectin
(hFN) (3 and 10 mg/ml, BD, Franklin Lakes, NJ) was used as positive control. Cells
maintained in the culture media until the end of each experiment. The cell seeding
density used in all experiments was 13 104 cell/cm2 except for the attachment assay
which was 5 3 104 cell/cm2.
Attachment assay. The attachment assay was performed as previously described41.
Details were described in supplementary information.
Determination of cell viability and proliferation.Cell viability and proliferationwas
determined using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
(MTT) mitochondrial activity assay as recommended by the manufacturer (Sigma,
Saint Louis, Missouri, US). Details were described in supplementary information.
Isolation of fibulin-1C protein from conditionedmedia ofHT1080 cells. Fibulin-1
C was purified from conditioned culture media (CCM) of HT1080 fibrosarcoma cells
that were stably transfected with full length coding sequence of fibulin-1C as
described by Tran et al 199742. Briefly, HT1080 cells were cultured in roller bottles for
5 days in serum-free DMEM.Media was collected and passed over a sepharose CL-4B
column and then over a column containing fibulin-1 antibody-conjugated sepharose.
After extensive washing, fibulin-1C was eluted using 3 M KSCN buffer. Peak
fractions were combined and dialyzed 2 times against 1003 volume of PBS. Fibulin-
1Cwas then passed over gelatin, heparin and wheat germ agglutinin (WGA) columns
sequentially and eluted from WGA with 0.5 M of N-acetylglucosamine in tris
buffered saline (TBS). Eluted fractions were dialyzed twice against 1003 volume of
TBS, aliquoted and stored at 220uC.
Detection of ECMproteins using ELISA. The detection of ECM FBLN1, fibronectin
(FN) and perlecan was done according to the methods described previously with
some modifications43. Details were described in online supplement.
Transforming growth factor (TGF) b1 ELISA. The supernatants were collected
from 12-well plates after three days of treatment with FBLN1C1. The levels of total
TGFb1 in the supernatants were measured using an ELISA kit according to the
manufacturer’s instructions (R&D Systems, Minneapolis, MN).
Statistical analysis. Data are expressed as mean 6 SEM. Statistical analysis was
performed using repeated measures one-way analysis of variance (ANOVA) and
Dunnett’s multiple comparison test or two-way ANOVA and Bonferroni post test
analysis as appropriate (GraphPad Prism 5.0).
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Figure 5 | Fibulin-1C peptide 1 (FBLN1C1) increases fibulin-1, fibronectin and perlecan deposition in lung fibroblasts. Fibroblasts were seeded in 96-
well plates, coated with (black bars) or without (PBS, open bars) FBLN1C1 10 mg/ml or with hFn 3 mg/ml (shaded bars), in 0.1% FBS DMEM. After 3
days, extra cellular matrix (ECM) was harvested and proteins were detected using ELISA. (a) ECM fibulin-1 (FBLN1) was determined using antibody
specific for FBLN1 N-terminal. Control N 5 5, chronic obstructive pulmonary disease (COPD) N 5 7, pulmonary fibrosis (PF) N 5 8. (b) ECM
fibronectin (FN) was determined using antibody specific for extra domain A of FN. Control N 5 5, COPD N 5 8, PF N 5 8. (c) ECM perlecan was
determined using antibody specific for clone 7B5. Control N5 4, COPD N5 7, PF N5 7. The results are absorbance subtracted with background and
expressed as mean 6 SEM. * P , 0.05, significantly different from PBS; two-way ANOVA with Bonferroni post test was performed.
Figure 6 | Fibulin-1C peptide 1 (FBLN1C1) decreases TGFb1 release in
lung fibroblasts. Fibroblasts were seeded in 12-well plates, coated with
(black bars), without FBLN1C1 10 mg/ml (PBS, open bars) or with plasma
fibronectin 3 mg/ml (shaded bars), in 0.1% FBS DMEM. After 3 days,
supernatants were collected and the levels of total soluble TGFb1 were
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